Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14323491 | 0.90 | CYP19A1 (0.59) | HDAC8HDAC6HDAC2CYP19A1DRD2 | |
| SCHEMBL14323714 | 0.87 | HDAC8 (0.63) | HDAC8HDAC6HDAC2CYP19A1HDAC1 | |
| SCHEMBL14323856 | 0.80 | HDAC6 (0.49) | HDAC8HDAC6HDAC2CYP19A1HSP90AB1 | |
| SCHEMBL14323724 | 0.77 | HDAC8 (0.64) | HDAC8HDAC6HDAC2CYP19A1HDAC1 | |
| SCHEMBL14322416 | 0.73 | DRD2 (0.50) | HDAC8HDAC6DRD2DRD4DRD3 | |
| SCHEMBL14324163 | 0.72 | DRD2 (0.55) | DRD2DRD4DRD3 | |
| SCHEMBL14324219 | 0.71 | DRD2 (0.57) | DRD2DRD4DRD3 | |
| SCHEMBL16199241 | 0.70 | HDAC8 (0.51) | HDAC8HDAC6HDAC2DRD2DRD4 | |
| SCHEMBL14323187 | 0.69 | CYP19A1 (0.60) | HDAC8HDAC6HDAC2CYP19A1HDAC1 | |
| SCHEMBL14323511 | 0.65 | DRD2 (0.54) | HDAC8DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871728-B2 | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | HDAC5, HDAC3, HDAC1 | HDAC8 9/4885HDAC6 11/4885HDAC2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.